Error loading player: No playable sources found

89825

Parallel Session 2 - How to Control Off Target Genotoxicity for Genome and Epigenome Editing Medicines

Date
June 11, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Genome editing is a tool that enables a new generation of medicines by directly targeting with high precision the genetic cause of a disease. It also allows for immune evasion and prevents microenvironment responses: concepts vital to more potent, off the shelf, cell, and gene therapies. To ensure safe and efficacious administration of gene edited products to patients, minimizing unintended effects is paramount. This session will review approaches to characterize off target genotoxicity at different stages of development for different class of genome/epigenome editing medicines. Current regulatory standards will be discussed, and lessons learned may be applied to relieve bottlenecks for future therapies. 


Session Speakers:


Overview of Current Genomic Analytical Tools to Enable Advancement of Investigational in vivo Genome Editing Products into Clinical Studies

Jessica Seitzer, Intellia Therapeutics, Inc.


Analytical Control Strategies for Ensuring Genomic Integrity in CAR-T Cell Therapies

Athea Vichas, Bristol-Myers Squibb Company


Off-Target Analysis of Genome Editing Products

Yongwook Choi, CBER, FDA



Additional Panelist:


Jennifer DashnauCentury Therapeutics, Inc.


Related Products

Thumbnail for Plenary Session 4 - Potency Assays for Gene Edited Products
Plenary Session 4 - Potency Assays for Gene Edited Products
Measurement of the biological activity is crucial for lot release, stability and any comparability exercise of all biological medicinal products…
Thumbnail for Plenary Session 1 - Genetic Modification Technologies for Cell-based Gene Therapies
Plenary Session 1 - Genetic Modification Technologies for Cell-based Gene Therapies
In addition to the now well-known CAR T (chimeric antigen receptor T cells) and HSC (CD34+ hematopoietic stem cells) cell-based gene therapies, there are several other modes of gene modification as well as cell types already approved and on the horizon…
Thumbnail for Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
Hot Topic Session - ICH Cell & Gene Therapy Discussion Group Updates
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together regulatory authorities and representatives from the pharmaceutical industry from across the globe to discuss a range of technical and scientific considerations for medicinal…